Difference between revisions of "Binimetinib (Mektovi)"
Jump to navigation
Jump to search
m |
|||
| Line 3: | Line 3: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| + | *[[Colorectal cancer, BRAF-mutated]] | ||
*[[Melanoma,_BRAF-mutated|BRAF-mutant melanoma]] | *[[Melanoma,_BRAF-mutated|BRAF-mutant melanoma]] | ||
*[[Melanoma,_NRAS-mutated|NRAS-mutant melanoma]] | *[[Melanoma,_NRAS-mutated|NRAS-mutant melanoma]] | ||
| Line 16: | Line 17: | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
[[Category:Mutation-specific medications]] | [[Category:Mutation-specific medications]] | ||
| − | |||
[[Category:MAP2K1 inhibitors]] | [[Category:MAP2K1 inhibitors]] | ||
[[Category:MAP2K2 inhibitors]] | [[Category:MAP2K2 inhibitors]] | ||
| + | [[Category:Colorectal cancer medications]] | ||
[[Category:Melanoma medications]] | [[Category:Melanoma medications]] | ||
[[Category:FDA approved in 2018]] | [[Category:FDA approved in 2018]] | ||
Revision as of 19:05, 8 May 2022
Mechanism of action
From the NCI Drug Dictionary: An orally available inhibitor of mitogen-activated protein kinase kinase 1 and 2 (MEK1/2) with potential antineoplastic activity. Binimetinib, noncompetitive with ATP, binds to and inhibits the activity of MEK1/2.
Diseases for which it is used
History of changes in FDA indication
- 6/27/2018: Initial FDA approval in combination with Encorafenib (Braftovi) for patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by an FDA-approved test. (Based on COLUMBUS)
Also known as
- Code names: ARRY-162, ARRY-438162, MEK162
- Brand names: Braftovi, Mektovi